Important Notice
New MOVANTIK National Drug Code (NDC) Numbers
Pharmacists, Healthcare Providers, and Patients
Please note the following new MOVANTIK NDCs:
- MOVANTIK 12.5 mg: 82625-8801-1
- MOVANTIK 25 mg: 82625-8802-1
MOVA-1123-332
Savings
Eligible patients can save with MOVANTIK
With the MOVANTIK Savings Card, eligible commercially insured patients can save on their MOVANTIK prescription and receive it for less than the cost of OTC laxatives.*
Access the MOVANTIK
Savings Card
Savings Card
*Subject to complete eligibility rules; restrictions apply. OTC laxatives include Colace®, Dulcolax®, ex-lax®, MiraLAX®, and Senokot®. Product names are registered trademarks of their respective owners. Pricing comparisons do not imply comparable efficacy, safety, or FDA-approved indications.
PATIENT INSTRUCTIONS: Present this offer to your pharmacist along with a valid prescription for MOVANTIK® (naloxegol) Tablets. Please call 312-896-0135 with questions and for full eligibility details.
TERMS AND CONDITIONS: Offer good for patients who meet eligibility criteria purchasing a 30-, 60-, or 90-day supply. Eligible commercially insured patients will pay as little as $0 for their monthly prescription, subject to a maximum benefit limit. Eligible uninsured (cash-paying) patients will receive savings on eligible out-of-pocket costs subject to a maximum benefit limit.
This program provides eligible patients with assistance to reduce out-of-pocket costs. By using this offer, patient and pharmacist understand and agree to comply with these terms and conditions. Only eligible U.S. residents may use this offer at participating pharmacies and may not redeem this offer at government-subsidized clinics. Offer user must be at least 18 years of age to use for themselves or on behalf of a minor. Patient age or insurance restrictions may apply.
Restrictions: No substitutions are permitted. Offer eligible only with valid prescription, has no cash value, and cannot be combined with any free trial, discount, prescription savings card, or other offer. This offer is not insurance. Valid only for patients with commercial insurance. This offer is NOT valid for prescriptions eligible to be reimbursed in whole or in part by Medicaid, Medicare (including Medicare Advantage and Part D plans), Veterans Affairs (VA), Department of Defense (DOD) programs or TriCare, or any other federally or state funded healthcare benefit program, or by commercial plans or health or pharmacy benefit programs that reimburse for the entire cost of the prescription drug or prohibit offer’s use. Medicare Part D enrollees who are in the prescription drug coverage gap are not eligible for offer. This offer is not transferable and is limited to one offer per person. Void were prohibited by law, taxed, or restricted. It is illegal to sell, purchase, trade, or counterfeit, or offer to sell, purchase, trade, or counterfeit the offer.
Valinor Pharma, LLC, reserves the right to rescind, revoke, or amend the offer at any time without notice.
Pharmacist instruction for a patient with an eligible Third-Party Payer: Submit the claim to the primary Third-Party Payer first, then submit the balance due as a Secondary Payer using Secondary Payer COB [coordination of benefits] with patient responsibility amount and a valid Other Coverage Code (eg, 8 or 3).
Pharmacist instruction for a cash-paying patient: Submit this claim as a Primary Payer using a valid Other Coverage Code (eg, 1).
For any questions regarding online processing, call the Pharmacy Help Desk at 312-896-0147.
INDICATIONS AND USAGE
MOVANTIK® (naloxegol) is an opioid antagonist indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation.
IMPORTANT SAFETY INFORMATION ABOUT MOVANTIK
CONTRAINDICATIONS
- MOVANTIK® is contraindicated in:
- Patients with known or suspected gastrointestinal obstruction and patients at risk of recurrent obstruction, due to the potential for gastrointestinal perforation.
- Patients concomitantly using strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) because these medications can significantly increase exposure to naloxegol, which may precipitate opioid withdrawal symptoms such as hyperhidrosis, chills, diarrhea, abdominal pain, anxiety, irritability, and yawning.
- Patients with a known serious or severe hypersensitivity reaction to MOVANTIK or any of its excipients.
WARNINGS AND PRECAUTIONS
- Opioid withdrawal: Clusters of symptoms consistent with opioid withdrawal, including hyperhidrosis, chills, diarrhea, abdominal pain, anxiety, irritability, and yawning, have occurred in patients treated with MOVANTIK. Additionally, patients receiving methadone as therapy for their pain condition were observed in clinical trials to have a higher frequency of gastrointestinal adverse reactions that may have been related to opioid withdrawal than patients receiving other opioids. Patients having disruptions to the blood-brain barrier may be at increased risk for opioid withdrawal or reduced analgesia. Consider the overall risk benefit in patients with disruptions to the blood-brain barrier. Monitor for symptoms of opioid withdrawal in such patients.
- Severe abdominal pain and/or diarrhea: Reports of severe abdominal pain and/or diarrhea have been reported, some of which resulted in hospitalization. Most of the cases of severe abdominal pain were reported in patients taking the 25 mg dosage. Symptoms generally occurred within a few days of initiation of MOVANTIK. Monitor patients for the development of abdominal pain and/or diarrhea with MOVANTIK and discontinue therapy if severe symptoms occur. Consider restarting MOVANTIK at 12.5 mg once daily, if appropriate.
- Gastrointestinal perforation: Cases of GI perforation have been reported with the use of peripherally acting opioid antagonists, including MOVANTIK. Postmarketing cases of GI perforation, including fatal cases, were reported when MOVANTIK was used in patients at risk of GI perforation (e.g., infiltrative gastrointestinal tract malignancy, recent gastrointestinal tract surgery, diverticular disease including diverticulitis, ischemic colitis, or concomitantly treated with bevacizumab). MOVANTIK is contraindicated in patients with known or suspected gastrointestinal obstruction or in patients at risk of recurrent obstruction. Take into account the overall risk-benefit profile when using MOVANTIK in patients with these conditions or other conditions which might result in impaired integrity of the gastrointestinal tract wall (e.g., Crohn’s disease). Monitor for severe, persistent, or worsening abdominal pain; discontinue MOVANTIK if this symptom develops.
ADVERSE REACTIONS
- The most common adverse reactions in clinical trials (≥3%) are: abdominal pain, diarrhea, nausea, flatulence, vomiting, headache, and hyperhidrosis.
DRUG INTERACTIONS
- Moderate CYP3A4 inhibitors (e.g., diltiazem, erythromycin, verapamil): Increased naloxegol concentrations; avoid concomitant use; if unavoidable, reduce dosage to 12.5 mg once daily and monitor for adverse reactions.
- Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, St. John’s Wort): Decreased concentrations of naloxegol; concomitant use is not recommended.
- Other opioid antagonists: Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use.
USE IN SPECIFIC POPULATIONS
- Pregnancy and lactation: The use of MOVANTIK during pregnancy may precipitate opioid withdrawal in the pregnant woman and the fetus. Because of the potential for adverse reactions, including opioid withdrawal in breastfed infants, advise women that breastfeeding is not recommended during treatment with MOVANTIK.
- Hepatic impairment: Avoid use of MOVANTIK in patients with severe hepatic impairment, as the dosage in these patients has not been determined. No dosage adjustment is required for patients with mild or moderate hepatic impairment.
- Renal impairment: In patients with creatinine clearance values <60 mL/minute (i.e., moderate, severe, or end-stage renal disease), a lower starting dosage of 12.5 mg once daily is recommended. No dosage adjustment is needed in patients with mild renal impairment.
To report SUSPECTED ADVERSE REACTIONS, contact Valinor at 1-877-592-2337 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Click here for the Medication Guide and full Prescribing Information for MOVANTIK.
This site is intended for US health care professionals only.
Think you have opioid-induced constipation?
Begin the quiz
Are you currently taking any opioid pain medication(s) for chronic non-cancer pain?
Select one
Submit
MOVANTIK is meant for people taking opioids in order to treat opioid-induced constipation in adults with chronic non-cancer pain.
If you’re experiencing constipation, talk to your doctor about your options for treatment.2,3
Go back
How many bowel movements do you have per week?
Select one
Submit
MOVANTIK is for the treatment of opioid-induced constipation in adults with chronic non-cancer pain. Having less than 3 bowel movements per week while taking opioids can be a symptom of opioid-induced constipation.
If you’re experiencing constipation, talk to your doctor
about your options for treatment.2,3
Go back
When completing a bowel movement, have you experienced any of the following?
Select all that apply
Submit
You may have opioid-induced constipation.1-3
Talk to you doctor about your symptoms and learn how
MOVANTIK may be able to help.
References: 1. Brock C, Olesen SS, Olesen AE, Frøkjaer JB, Andresen T, Drewes AM. Opioid-induced bowel dysfunction: pathophysiology and management. Drugs. 2012;72:1847-1865. 2. MOVANTIK® (naloxegol). Prescribing information. Valinor Pharma, LLC; 2023. 3. Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014;370:2387-2396.
Coverage for the #1 prescribed oral
PAMORA just got even better1
*Data as of June 2021.3
Plans and coverage may vary and are subject to change. General information only, not a guarantee of coverage. Coverage and status do not imply efficacy or safety.
PAMORA=peripherally acting mu-opioid receptor antagonist; PDP=prescription drug plan.
References: 1. Data on file. Prescription data. Valinor Pharma, LLC; 2023. 2. Data on file. Prime Therapeutics formulary coverage. Valinor Pharma, LLC; 2023. 3. Data on file. Cigna formulary coverage. Valinor Pharma, LLC; 2023.